“Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis”. 2024. SKIN The Journal of Cutaneous Medicine 8 (1): s313. https://doi.org/10.25251/skin.8.supp.313.